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Leptomeningeal metastases in breast 
cancer patients — current rules  
of diagnosis and treatment
ABSTRACT
Leptomeningeal metastases (LM) presents a challenge because of the difficulty in determining the diagnosis and 
lack of optimal therapy. Nowadays, LM are more frequently diagnosed as a consequence of the long survival of 
patients with breast cancer and the improvement in image analysis. LM is a deleterious complication of breast 
cancer leading to death of patients within less than 3–6 months from the diagnosis. No generally accepted 
standard of care in the treatment of breast cancer LM exists. The treatment of patients with breast cancer and 
LM is of limited efficacy and substantial toxicity. Usually it requires focal radiotherapy to symptomatic sites or 
areas of bulky disease, intra-cerebrospinal fluid chemotherapy, or systemic intravenous/oral therapy, but the data 
regarding the sequence and efficacy of particular types of treatment are disputable. The management of breast 
cancer patients with LM was reviewed based on the data from literature. Additionally, the results of randomised 
clinical trials were reviewed.
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Introduction
Leptomeningeal metastases (LM) of solid tumours, 
in Polish literature also called cancerous leptomeningitis, 
comprises the presence of cancer cells in the subarach-
noid cavity (in cerebrospinal fluid and/or in leptome-
ninges). In Anglo-Saxon terminology LM or neoplastic 
meningitis are used to describe cancerous involvement 
of leptomeninges that originate from different organs 
(lymphomas, gliomas, carcinomas, and malignant mela-
nomas). Terms such as carcinomatous meningitis, menin-
geal carcinomatosis, or leptomeningeal carcinomatosis 
define the presence of carcinoma cells in leptomeninges 
(most commonly from breast cancer, small cell and 
non-small cell lung cancer, and gastrointestinal cancers). 
The rate of diagnosis of leptomeningeal metastases 
is growing, mostly due to the prolonged survival of 
cancer patients and improved imaging. About 5–15% of 
patients with lymphoma or leukaemia and about 1–8% 
of patients with carcinoma develop LM [1–7]. 
The longest survivals of patients with leptomenin-
geal metastases are observed in breast cancer [1–3, 5, 
8–11]. Nearly 60% of patients in this group respond 
to treatment, with responses lasting about 3–6 months 
(median 4 months) [5, 12–16]. However, only 10–15% 
of treated patients remain alive for over one year [3, 
13, 14]. Patients without treatment, with unfavourable 
risk factors, survive only 4–6 weeks [6]. Metastases in 
different organs are found simultaneously in 70–90% 
of patients [4–6, 17, 18], with parenchymal brain me-
tastases in nearly 50% of them [1, 4, 18]. Breast cancer 
subtypes with the highest rates of LM are triple-negative 
breast cancers and, among histological subtypes, lobular 
carcinoma [13]. 
Currently, no strict guidelines for a therapeutic 
approach in LM of breast cancer exist. Only a few ran-
domised clinical trials have addressed this matter (most 
of them regarding intrathecal drug administration), and 
most of them included different cancer types, with breast 
cancer cohorts limited to 35 patients at best. No single 
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treatment response criterion has been established yet 
because changes observed in radiological imaging and in 
cerebrospinal fluid analyses do not always correlate with 
clinical response and performance status [11, 18–20]. 
In this review, we present up-to-date data about the 
pathophysiology, clinical symptoms, diagnosis, and treat-
ment of leptomeningeal metastases of breast cancer. 
Pathophysiology
The subarachnoideal cavity, which separates the 
arachnoid mater and pia mater, contains approximately 
140 ml of cerebrospinal fluid, a volume that is similar 
in every person. The amount of fluid produced daily 
is estimated to be 600–800 ml, and given the constant 
reabsorption, the whole volume of cerebrospinal fluid 
is exchanged several times per day [4, 5]. Cancer cells 
that enter the cerebrospinal fluid usually relocate 
gravitationally to the posterior cranial fossa and the 
lumbosacral part of the spinal canal [5]. In the next 
stage, they infiltrate the surface of brain, cranial nerves, 
spinal cord, and spinal nerves roots [3, 6, 21]. Metasta-
ses may grow as a diffused infiltration along meninges 
or may form nodes (most often in posteriori cranial 
fossa and in cauda equina). The presence of neoplastic 
growth in meninges often results in a diversified degree 
of local inflammation [1]. Cerebral fluid examination 
usually reveals pleocytosis (stimulated lymphocytes 
and monocytes) [4, 6]. Fibrosis limits cancer growth 
but also leads to a narrowing of blood vessels, local 
ischaemia, altered neural metabolism, and permanent 
nerve damage [4, 22]. 
Clinical signs
Clinical signs of leptomeningeal metastases are 
usually an effect of pressure and infiltration of neural 
tissue in the following: 1) cerebrum and cerebellum, 
2) spinal cord, 3) cranial nerves, and 4) spinal nerves 
roots. Implantation of cancer cells in different parts 
of the subarachnoid cavity results in simultaneous oc-
currence of multifocal neurological defects [1–6, 11, 
18–20]. Signs from cerebrum and cerebellum include 
strong headache, nausea, vomiting, memory impair-
ment, changes in personality, altered mental states, 
drowsiness, signs of meningeal irritation, and coma. 
Nerve dysfunction affects most often III, IV, VI, and VII 
cranial nerves, but every nerve, even II and VIII, might 
be involved. Metastases in spinal cord may induce signs 
such as radicular pain (usually in a lumbar area of the 
vertebrae and in the back of the neck), paraesthesia and 
pain in limbs, muscle weakness, and faecal and urinary 
incontinence [2–6, 13–15, 19]. 
Diagnosis
Diagnosis of leptomeningeal metastases relies 
on confirmation of a triad of signs (“gold standard”) 
that include:
 — clinical presentation of a number of different neuro-
logical syndromes that occur with different intensity;
 — abnormal results of cerebrospinal fluid, which 
include the presence of cancer cells, polycytosis, 
increased protein, and decreased glucose concen-
tration;
 — the presence of metastases in magnetic resonance 
imaging (MRI).
The most important test that confirms diagnosis of 
LM is the detection of cancer cells in the cerebrospi-
nal fluid [1–5, 11, 19, 20]. However, diagnosis cannot 
be excluded even in absence of the triad presented 
above. Evidence of the existence of cancer cells in the 
cerebrospinal fluid with the presence of neurological 
signs with normal MRI results, as well as the presence of 
neurological signs with a meningeal infiltration detected 
in MRI without cancer cells in cerebrospinal fluid, are 
sufficient to confirm the diagnosis. However, it should be 
emphasised that the presence of neurological symptoms 
with atypical cytosis without evidence of cancer cells in 
the cerebrospinal are insufficient to confirm diagnosis 
and foreclose eventual treatment. The probability of 
LM in such situations is significant, but not certain, and 
justifies repetition of lumbar puncture and MRI [11].
Recent studies have tried to assess the value of 
testing EpCAM (epithelial cell adhesion molecule) 
concentration in cerebrospinal fluid as a marker of LM, 
especially in cases with absence of cancer cells [23, 24].
The most effective method of radiological imaging in 
case of LM suspicion is magnetic resonance imaging with 
contrast. It allows detection of changes such as a linear 
meningeal infiltration, nodule formation in pia mater, 
hydrocephalus, and nerves thickening [2–5]. 
Prognostic factors
An adequate assessment of prognostic factors in 
LM allows the selection of subgroups of patients with 
a favourable prognosis, who could benefit from intensi-
fied oncological treatment (despite palliative setting), 
and patients with an unfavourable prognosis, who would 
only need best supportive care.
Patients with a poor performance status — with 
a vast nervous system infiltration that results in encepha-
lopathy, with disturbances in the cerebrospinal fluid 
circulation, with major neurological defects, or with an 
uncontrolled systemic involvement of different organs 
(metastases in several parenchymal organs) — have poor 
prognosis and should receive only best supportive care 
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or treatment limited to the radiotherapy of sites respon-
sible for neurological symptoms. In contrast, patients 
with adequate performance status — with limited LM, 
without major neurological defects, with maintained 
cerebrospinal fluid circulation, with a controlled or po-
tentially controlled metastases in other organs, and with 
a probability of survival over three months — should be 
treated with available oncological modalities with the 
aim of prolonging survival and improving quality of life 
[1, 3, 5, 6, 8, 9, 20, 25–27]. 
The most important prognostic factor that deter-
mines overall survival and treatment effectiveness is the 
patient’s performance status [8, 13, 14, 28]. 
Treatment
According to the USA National Comprehensive Can-
cer Network (USA NCCN), patients with an unfavour-
able prognostic factors should receive best supportive 
care (corticosteroids and/or analgesic drugs, antidepres-
sants, anxiolytics, and anticonvulsants) and — whenever 
appropriate — radiotherapy of the areas causing symp-
toms [27]. In patients with significantly increased intrac-
ranial pressure, implantation of a ventriculo-peritoneal 
shunt should be considered as a supportive treatment.
Treatment modalities for patients with favourable 
prognostic factors include radiotherapy, cytotoxic drugs 
administered to the subarachnoideal cavity (intrathecal 
chemotherapy), and/or systemic treatment (chemother-
apy, hormonal therapy, targeted therapy). Therapy aims 
at improving quality of life by mitigation of neurological 
symptoms and pain reduction, and at prolonging survival 
[1–4, 19]. Currently, no standard treatment sequence 
exists [3, 18–20, 29], especially among heavily pretreated 
patients, in whom selection of active therapy with an ac-
ceptable toxicity profile might be problematic. According 
to the USA NCCN, in patients with favourable prognostic 
factors, recommended proceedings include cerebrospinal 
fluid circulation assessment, with sequential provision of 
radiotherapy for the areas that restrict circulation, and 
then subsequent administration of intrathecal or systemic 
treatment [27]. However, this approach is not commonly 
recognised as a standard. Different approaches include 
beginning the therapy with intrathecal administration of 
cytotoxic drugs if numerous cancer cells are found in cere-
brospinal fluid analysis, as a way to improve cerebrospinal 
fluid circulation by decreasing the fluid stickiness. Also, 
in the case of numerous nodular metastases, significant 
meningeal infiltration (with a profound pathological 
vascularisation), or uncontrolled metastases in differ-
ent organs, systemic treatment should be considered as 
a primary treatment modality [7, 30]. The decision about 
treatment sequence and its further modifications should 
be taken by an experienced interdisciplinary team. 
Radiotherapy
The most common indications for radiotherapy 
include: presence of neurological symptoms, existence 
of a vast cancerous infiltration of the meninges, and 
changes that restrict cerebrospinal fluid circulation 
[1–6, 8, 9, 12, 25, 26, 31]. A total dose of 30 Gy in 
10 daily fractions of 3 Gy is usually given [1, 4, 5, 32–34]. 
However, no randomised controlled trial regarding 
the effectiveness of the radiotherapy in LM has yet 
been undertaken.
Intrathecal therapy
One of the most controversial areas of LM treatment 
is intrathecal administration of cytotoxic drugs. In the 
majority of studies, no effect on survival prolongation 
was shown, with responses limited to the mitigation 
of symptoms and an improvement in neurological 
status. Frequent and severe side effects related to the 
intrathecal drug administration significantly limit its 
application. 
Currently available drugs used for the intrathecal 
administration are methotrexate, thiotepa, and cytosine 
arabinoside, called also cytarabine, in a conventional 
or liposomal formulation. Routes of administration 
include lumbar puncture (intrathecal administration) 
and delivery to lateral ventricles of the brain by an 
implanted subcutaneous Ommay or Rickham reservoir 
(intraventricular administration) [4, 7]. Intraventricular 
administration is more convenient for the patient and 
is better tolerated but may be linked to some severe 
side effects such as intraventricular bleeding or central 
nervous system infection [35–37]. 
Thus far, only six randomised clinical trials regard-
ing leptomeningeal metastases from solid tumours or 
lymphomas have been performed [26, 38–42]. All of 
them included intrathecal drug administration. Only five 
of six trials included breast cancer patients (with a total 
number of 129 breast cancer patients in all trials), and 
only one trial was dedicated only to such patients [41]. 
Cohorts included in the studies numbered from 28 to 
103 patients. Trials compared effectiveness between 
different single drugs administered intrathecally, or 
between a single drug and a two drug combination. In 
solid tumours a two-drug combination was not superior 
to a one-drug intrathecal therapy, and no single drug was 
significantly superior to others. However, in the treat-
ment of lymphomas, liposomal cytarabine was shown 
to be more effective than methotrexate. In all of the 
discussed randomised controlled trials mean survival 
of the breast cancer patients treated intrathecally was 
15 weeks [43].
A randomised clinical trial by Glantz et al. [40] 
compared the effectiveness of methotrexate and li-
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posomal cytarabine in 61 patients with LM from solid 
tumours (including 22 patients with breast cancer). 
Both methotrexate and liposomal cytarabine induced 
similar response rates — 26% and 20% (p = 0.76), re-
spectively — and comparable median overall survival of 
appropriately 105 and 78 days, respectively (p = 0.15). 
Nevertheless, a statistically significant longer time to 
neurological progression was observed in the arm with 
liposomal cytarabine (58 days vs. 30 days; p = 0.007). 
Rates of drug-induced meningitis were similar between 
compared arms (23% after liposomal cytarabine and 
19% after methotrexate, p = 0.57). An additional ad-
vantage of liposomal cytarabine was administration at 
longer intervals (six cytarabine administration equalled 
16 administrations of methotrexate). 
A randomised clinical trial by Boogerd et al. in-
cluded 35 breast cancer patients with LM [41]. The aim 
of the study was to assess value of an intraventricular 
treatment. In the first arm the patients received ra-
diotherapy and systemic treatment only, and in the 
second arm patients additionally received intraven-
tricular treatment with methotrexate. The addition of 
intraventricular treatment did not improve patients’ 
survival and significantly increased toxicity rates. Me-
dian progression free survival was 23 weeks in the arm 
with intraventricular methotrexate and 24 weeks in the 
arm without. Median survival was 18 weeks in the group 
receiving methotrexate and 30 weeks (p = 0.32) in the 
arm without intraventricular treatment. Nearly 47% 
patients in the methotrexate arm group experienced 
side effects, such as headaches, impaired conscious-
ness, drug-induced meningitis, infection, and leukoen-
cephalopathy if the cumulative drug dose reached 
150–170 mg. The adverse event rate in the arm without 
intraventricular treatment reached 6% (p = 0.007). On 
the basis of the presented data, the authors concluded 
that in breast cancer patients with LM a combination of 
systemic therapy and radiotherapy is the primary treat-
ment option, and that the addition of intraventricular 
chemotherapy is dispensable.
In our retrospective study, based on a cohort of 
149 patients with breast cancer and leptomeningeal 
metastases, we compared outcomes and effectiveness of 
intrathecal methotrexate and liposomal cytarabine [14]. 
No significant differences between methotrexate and 
liposomal cytarabine were seen in terms of effectiveness 
(median overall survival 4.2 vs. 4.6 months (p = 0.546), 
respectively). However, liposomal cytarabine usage was 
more convenient due to longer intervals between drug 
administrations. Liposomal cytarabine should be con-
sidered a treatment of choice in patients with impaired 
mobility because of neurological symptoms and in pa-
tients living at a significant distance from a treatment 
centre (fewer hospital visits). The major disadvantage of 
liposomal cytarabine, when compared to methotrexate, 
is its higher treatment costs.  
Cytotoxic drugs administered to the subarachnoid 
cavity often induce severe adverse events. Early and 
late toxicities might be distinguished. In 10–25% of pa-
tients acute, drug-induced, aseptic meningitis occurs [7]. 
Usually symptoms begin within a few hours after drug 
administration. The diagnosis requires the occurrence 
of stiffness and pain in the neck and another two symp-
toms from the following: headache, nausea, vomiting, 
pain in the back, fever, impaired consciousness, coma, 
pleocytosis in a cerebrospinal fluid analysis without the 
presence of cancer cells, and negative cerebrospinal 
fluid cultures [6, 7, 11, 38, 40]. Treatment includes 
corticosteroids and nonsteroidal anti-inflammatory 
drugs. Normally, symptoms resolve within three days [7]. 
The rate of occurrence of drug-induced meningitis after 
administration of liposomal cytarabine, which typically 
presents as cauda equina or conus medullaris syndrome, 
is estimated at about 17% [7]. In such cases intravenous 
corticosteroid treatment should be introduced. 
The most common late adverse event, which may 
arise in 10–25% of patients receiving intrathecal treat-
ment, is leukoencephalopathy [1–3, 5–7, 25, 44, 45]. 
Clinical symptoms include progressive and irreversible 
decrepitude with cognitive function impairment, focal 
neurological signs, bowel and urinary constrictor dys-
function, and seizures. In T2-weighted magnetic reso-
nance imaging, hyperintense changes in periventricular 
white matter can be detected [41].
Systemic treatment
Most of the patients diagnosed with LM also have 
metastases in different organs and therefore require 
systemic therapy. Until recently, systemic treatment was 
considered ineffective in cases of leptomeningeal metas-
tases, due to the robustness of the blood-brain barrier. 
However, cancer cell infiltration disrupts the blood-brain 
barrier and, along with pathological vascularisation cre-
ated by metastases growing in meninges, provides an 
opportunity for drugs to diffuse from the blood to the 
cerebrospinal fluid in the subarachnoideal cavity. 
Several studies, mostly published after 2004, provide 
evidence for the activity of systemic therapy adminis-
tered intravenously and orally in the management of 
patients with LM, and is the only treatment modality that 
showed prolongation of patients’ survival [13–16, 28, 41, 
45–47]. Our previous reports showed that even though 
intrathecal therapy and radiotherapy play an important 
role in enhancing patients’ quality of life, only systemic 
therapy provides a statistically significant improvement 
in overall survival [13, 14].
The role of hormonal therapy in breast cancer 
patients with LM is uncertain, although tamoxifen and 
aromatase inhibitors can cross the blood-brain barrier, 
and a single study reports neurological and cytological 
improvement after hormonal therapy [48]. 
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Novel therapies
Several ongoing studies are evaluating the effec-
tiveness of non-standard drugs administered intrathe-
cally, including mafosfamide, nitrosourea, gemcitabine, 
etoposide, topotecan, trastuzumab, rituximab, and inter-
feron a. Various intravenous drugs, not yet evaluated in 
the setting of breast cancer leptomeningeal metastases, 
are under investigation (nitrosourea, etoposide, lipo-
somal doxorubicin, interleukin-2, gefitinib, erlotinib, 
vemurafenib, dabrafenib, rituximab, and trastuzumab) 
[1, 4, 7, 46, 47].
Significant hope is placed in trastuzumab adminis-
tered into the subarachnoideal cavity. No randomised 
clinical trial of intrathecal trastuzumab has been carried 
out, but several case reports and the analysis of a cohort 
of 17 patients have been published [47]. In the presented 
cases, trastuzumab was administered intrathecally in dif-
ferent schemes and in various doses (ranging from 4 mg 
to 150 mg). In some of the cases it was combined with 
intrathecal methotrexate or liposomal cytarabine, and in 
others concurrent systemic therapy was used (with tras-
tuzumab, paclitaxel, capecitabine, cisplatin, etoposide, 
or doxorubicin). A clinical improvement was obtained 
in 68% of cases, and a regression in cerebrospinal fluid 
analysis was seen in 66% of patients. Achieved responses 
did not translate into improved overall survival, but they 
had an influence on the prolongation of the time to neu-
rological progression. The authors of the cohort analysis 
concluded that trastuzumab, used alone or in combina-
tion with different drugs, is a safe option of palliative 
treatment, which leads to clinical improvement in some 
patients [47]. However, the small number of analysed 
patients, selection bias regarding reported cases, and 
several cases of combination therapy with intrathecal and 
systematic treatment make evaluation of trastuzumab 
in this setting impossible. Moreover, the therapy effects 
were limited to a palliation of symptoms, and no gain 
in survival was observed. There remains the need for 
a randomised clinical trial in order to fully evaluate the 
effectiveness of trastuzumab administered intrathecally 
in breast cancer patients with leptomeningeal metastases.
Problems to solve 
The limited effectiveness and high toxicity of the 
currently used treatment for LM justifies further stud-
ies regarding optimal treatment schedules and reliable 
ways of assessing treatment responses. Several problems 
await resolu tion. 
Firstly, it not yet known whether intrathecal/intra-
ventricular treatment in breast cancer patients with 
LM is as effective as in cancers originating from the 
lymphatic system and whether it should be routinely 
used, considering its substantial toxicity and probable 
limited effect on overall survival. 
Secondly, if we consider intrathecal/intraventricular 
treatment only as way of palliating symptoms, toxicity 
assessment is a priority. Nevertheless, published stud-
ies often lack data regarding the side effects associated 
with the treatment.
Thirdly, despite the proven value of systemic treat-
ment in breast cancer LM, its optimal place in a se-
quence with radiotherapy and intrathecal therapy is 
not yet determined.
Fourthly, clinical trials have shown that, at present, 
there is no effective way of assessing treatment response 
in patients with leptomeningeal metastases. Complete 
cytological response (disappearance of cancer cells 
form cerebrospinal fluid) has no effect on prolongation 
of patients’ survival. Overall survival depends more 
on the neurological rather than cytological response, 
despite the difficulties in evaluating neurological 
responses. Without standardisation of neurological 
examination, we lack a strict and accurate method of 
assessing progression or regression of the disease [24]. 
Radiological imaging also has limited effectiveness, as 
the extensity of changes determined in MRI does not 
correlate with the neurological state or performance 
status of patients. Paradoxically, treatment effects seen 
as an improvement in patients’ symptoms might occur 
even without any regression seen in radiological imaging.
The problems presented above forced the group of 
experts in the field of leptomeningeal metastases (Inter-
national Panel of Experts US and Europe The RANO 
Group — Response Assessment in Neuro-Oncology) 
to critically analyse available data from randomised 
clinical trials and to draw possible long-term strategies 
for improvement in diagnostic, treatment, and response 
evaluation in patients with LM from solid tumours [18]. 
It seems that overall survival rates at 6 and 12 months are 
the most objective points for assessing treatment effec-
tiveness and for comparing different groups with LM [43]. 
Conclusions
Currently, no strict guidelines for the therapy of 
breast cancer patients with leptomeningeal metastases 
exist. Systemic chemotherapy is the only therapeutic 
modality that significantly prolongs survival and allows 
control of metastases in locations other than menin-
geal. Intrathecal therapy and radiotherapy seem to not 
extend survival, but they can improve quality of life and 
therefore are a vital part of palliative treatment. Due to 
disappointing effects of LM treatment, there is an urgent 
need for a standardisation of response evaluation and 
implementation of new therapies originating from good 
quality randomised clinical trials.
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